November 24, 2022
Late Stage Cancer
September 23, 2022
ASCO: Bristol Myers touts 2 Opdivo esophageal cancer wins, but the Yervoy combo comes with a caveat
https://www.fiercepharma.com/pharma/bristol-myers-touts-2-opdivo-esophageal-cancer-wins-but-yervoy-combo-sees-a-caveat
September 3, 2022
Which Chemo-IO Combo is Optimal in First-Line Esophageal Cancer?
https://www.ajmc.com/view/which-chemo-io-combo-is-optimal-in-first-line-esophageal-cancer-
August 13, 2022
Immunotherapy Combination Selection Is Driven by PD-L1 in Gastroesophageal Cancer
https://www.onclive.com/view/immunotherapy-combination-selection-is-driven-by-pd-l1-in-gastroesophageal-cancer
August 4, 2022
Bristol Myers Squibb, on a roll, touts 2 Opdivo GI cancer wins—including one earlier in treatment
https://www.fiercepharma.com/marketing/bristol-myers-squibb-a-roll-touts-2-opdivo-gi-cancer-wins
July 2, 2022
Frontline Tislelizumab Plus Chemo Achieves 34% Reduction in Risk of Death in Advanced ESCC
https://www.targetedonc.com/view/frontline-tislelizumab-plus-chemo-achieves-34-reduction-in-risk-of-death-in-advanced-escc
July 1, 2022
Novartis’ tislelizumab shows promising survival results in advanced esophageal cancer, Phase 3 data reveals
https://www.financialexpress.com/healthcare/pharma-healthcare/novartis-tislelizumab-shows-promising-survival-results-in-advanced-esophageal-cancer-phase-3-data-reveals/2578524/
June 30, 2022
New Phase III data show Novartis tislelizumab significantly extended median overall survival by more than 6 months in first-line advanced esophageal cancer in combination with chemotherapy
https://www.globenewswire.com/news-release/2022/06/30/2471828/0/en/New-Phase-III-data-show-Novartis-tislelizumab-significantly-extended-median-overall-survival-by-more-than-6-months-in-first-line-advanced-esophageal-cancer-in-combination-with-chem.html
June 3, 2022